Keywords: Boehring Ingelheim, Eli Lilly, Jentadueto, Pradaxa, EMA, Type 2 diabetes, Anticoagulant, Blood thinner

EMA unit backs approval of Jentadueto; Agency updates on Pradaxa

Article | 28 May 2012

Print This

Independent German drug major Boehringer Ingelheim and US partner Eli Lilly (NYSE: LLY) have received a positive opinion ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in